ClinicalTrials.gg
RecruitingNCT07481253COMPATiUpdated Sep 10, 2026

PSYCHOPATHY.COMP Program Among Male Prison Inmates With Psychopathy

An interventional study of PSYCHOPATHY.COMP and Treatment as Usual (TAU) in Antisocial Personality Disorder (ASPD), sponsored by University of Coimbra. Recruiting at 1 site in Portugal. Open to male participants aged 19 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by University of Coimbra · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
19 Years to 30 Years
Sex
Male
01

Study summary

The goal of this clinical trial is to learn whether PSYCHOPATHY.COMP, an individual compassion-focused, therapy-based intervention of 20 weekly sessions, can reduce psychopathy in prison inmates. Psychopathy is linked with the most severe and persistent forms of antisocial behavior. This trial will also learn whether the program improves emotional and behavioral regulation.

The main questions are:

  • Does PSYCHOPATHY.COMP reduce psychopathy?
  • Does PSYCHOPATHY.COMP improve emotional and behavioral regulation? Researchers will compare PSYCHOPATHY.COMP with the usual individual case management support provided in prisons.

Portuguese-speaking adult male prison inmates will be invited to participate. Those who consent to participate will be screened for inclusion (T0). A total of 200 eligible participants will take part. All participants will be invited to complete a baseline assessment (T1, pre-treatment assessment), after which they will be randomly assigned to receive PSYCHOPATHY.COMP or the usual care provided in the prison for a period of around six months. All participants will be invited to complete a post-treatment assessment (T2) and a six-month follow-up assessment post-treatment. Assessments will collect data on sociodemographic characteristics and legal/criminal information, psychological outcomes (psychopathy, emotional regulation, and behavioral regulation), psychological mediators (mechanisms of change: compassion-related variables), and moderators (personality pathology), and data on social desirability.

This study aims to contribute to advancing scientific knowledge about whether and how to reduce psychopathy among prison inmates and have an impact on clinical practice and society by making available evidence-based interventions to this at-risk/high-risk population.

Read the detailed description

There has long been interest in the study of psychopathy, defined as a set of interpersonal (e.g., grandiosity, manipulation), affective (e.g., callousness, unemotionality), deviant lifestyle (e.g., impulsivity, irresponsibility), and antisocial traits (e.g., criminal versatility). Psychopathy is usually associated with the most severe and persistent forms of antisocial behavior, being a strong predictor of violent behavior and overall criminal recidivism. Given that inmates with psychopathy represent 15-40% of the in-prison population (depending on the risk level of the sample and type of crime), delivering evidence-based interventions specifically tailored to their needs, mitigating the clinical and societal costs of psychopathy and antisocial behavior, is of utmost relevance.

To our knowledge, the PSYCHOPATHY.COMP is the first program specifically designed to reduce psychopathy and antisocial behavior through the promotion of a compassionate motivation. PSYCHOPATHY.COMP consists of a structured, individual, 20-session therapy-based intervention based on Compassion Focused Therapy (CFT). Results from a (nonrandomized) controlled clinical trial showed that the PSYCHOPATHY.COMP is an effective treatment for reducing psychopathic traits and disruptive behavior in detained youth, as well as for promoting compassionate motivation and emotion regulation (medium/large effect sizes), with compassionate motivation having a significant mediating effect on the changeability of psychopathic traits. Results showed treatment effects were sustained for up to six months after the intervention. Despite these findings, it is unknown whether prison inmates with psychopathy can benefit from this program, as they are considered more resistant to treatment than their youth counterparts. This project aims to test the efficacy of the PSYCHOPATHY.COMP in reducing psychopathic traits, as well as in promoting emotion and behavior regulation among male adults (19-30 years; developmentally closer age range of detained youth) prison inmates through the promotion of a compassionate motivation.

COMPATi aims to test the efficacy of the PSYCHOPATHY.COMP among adult male prison inmates with antisocial personality disorder (ASPD) and high levels of psychopathic traits. Specifically, it aims to:

PRIMARY GOALS:

  1. Test the efficacy of the PSYCHOPATHY.COMP in reducing psychopathic traits (primary outcome) when compared with Treatment as Usual (TAU) within one month after the treatment completion, and assess the stability of change up to six months after treatment,

    SECONDARY GOALS:

  2. Test the efficacy of the PSYCHOPATHY.COMP in promoting emotion and behavior regulation (secondary outcomes) when compared with TAU within one month after the treatment completion, and assess the stability of change up to six months after treatment,
  3. Assess the mediating role of change in compassion-related variables on the efficacy of the PSYCHOPATHY.COMP,
  4. Assess the moderating effect of personality pathology on the efficacy of the PSYCHOPATHY.COMP.

This is a pre-registered, multi-center, two-arm, parallel, blinded (by data analysts), randomized controlled trial (RCT) with 1:1 computer-generated, blocked randomized allocation to treatment (allocated to receive PSYCHOPATHY.COMP) or control (allocated to receive the treatment as usual - TAU) groups. A total of 200 Portuguese-speaking adult male prison inmates are estimated to be recruited from 10 randomly selected high-security male prisons in Portugal, for a total of 19 prisons. Male prison inmates are consecutively screened for inclusion (T0). Those who consent to participate and meet the inclusion criteria are invited to complete the baseline T1 assessment. After the T1 assessment, participants are randomly allocated to the treatment or control groups. PSYCHOPATHY.COMP is delivered by psychologists (including those from prisons) for about 6 months. Treatment integrity will be ensured by following established recommendations: psychologists will be trained (through an intensive, face-to-face 5-day training) and supervised (one session per month) during the delivery of the intervention (training/supervision is carried out by the research team members); therapists and participants will rate every session on their subjective perception regarding the usefulness of the session and the therapeutic relationship (therapist will also rate every session on their subjective perception regarding how they follow the manualized protocol of the session and their overall rating of the sessions); as sessions cannot be audio- or video-recorded for ethical reasons, CFT experts from the research team will observe and rate 20% of the sessions using a measure of treatment integrity for the CFT approach. All participants are then invited to complete an assessment within one month after treatment (T2) and a follow-up assessment at 6 months post-treatment (T3). Assessments will collect sociodemographic and legal/criminal data (at T1), data on psychological mediators (compassion-related variables; at T1-T3), and outcomes. In this latter, psychopathy (primary outcome) will be assessed at T0-T3, emotional regulation (secondary outcome) at T1-T3, and behavioral regulation (secondary outcome) will be observed over time, covering the period from T0 to T3. Social desirability will also be controlled for and assessed at T1-T3. The evaluation of personality pathology (psychological moderator) will be conducted at eligibility (T0, for ASPD) and at baseline (T1, for other personality disorders) using a structured clinical interview. All assessments rely on self-report and observable data (collected from prison record files) and are conducted by the research team.

A priori power analyses estimate that a minimum of 171 participants is necessary to detect medium effects (significance level of .05, power of .90). Accounting for participation and attrition rates, a minimum of 200 individuals need to be recruited.

Results aim to provide foundational knowledge of PSYCHOPATHY.COMP's efficacy among prison inmates. Results will inform the potential benefits and implementation of PSYCHOPATHY.COMP in prison settings in Portugal and its potential translation to other countries, helping to answer the clinical and societal need to make available evidence-based interventions to this at-risk/high-risk population.

02

Conditions studied

  • Antisocial Personality Disorder (ASPD)

Keywords

  • Antisocial behavior
  • Institutional behavior
  • Criminality
  • PSYCHOPATHY.COMP
  • Compassion Focused Therapy
  • Psychopathy
03

In context

Antisocial Personality Disorder

67 studies on the registry are indexed under Antisocial Personality Disorder; 10 are open to participants now.

This study's planned enrollment of 200 is above the median of 140 across 43 interventional studies indexed under Antisocial Personality Disorder.

Browse Antisocial Personality Disorder studies →

Lead sponsor

University of Coimbra is the lead sponsor of 89 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 30 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male prison inmates,
  • Portuguese-speaking,
  • aged between 19 and 30 years
  • having at least one prior case in the juvenile justice system in which a judicial measure was applied,
  • with high levels of psychopathic traits (measured with the SRP-SF and LSRPS self-reported questionnaires)
  • with an Antisocial Personality Disorder (ASPD) diagnosis (measured with the SCID-II)

Exclusion criteria

Exclusion criteria:

  • suspected psychotic/autism spectrum disorders and/or cognitive impairments,
  • female,
  • sentence length inferior to 24 months since the start of the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Treatment

    PSYCHOPATHY.COMP

    Behavioral: PSYCHOPATHY.COMP

  • Active comparator
    Control

    Treatment as Usual (TAU)

    Other: Treatment as Usual (TAU)

Interventions

  • BehavioralPSYCHOPATHY.COMP

    Participants allocated to the treatment group will receive PSYCHOPATHY.COMP. PSYCHOPATHY.COMP is a manualized intervention of 20 weekly 60-min sessions (\~6 months) rooted in Compassion Focused Therapy (CFT). PSYCHOPATHY.COMP follows a progressive strategy of change in four modules: (1) The basics of our mind; (2) Our mind according to CFT; (3) Compassionate Mind Training; and (4) Recovery, relapse and prevention. As a common feature of all therapeutic sessions, therapists are focused on developing a secure therapeutic relationship. PSYCHOPATHY.COMP is delivered by psychologists skilled in CFT (including those from prisons). Psychologists will be trained (through an intensive, face-to-face 5-day training) and supervised (one session/month) by the research team during the delivery of the intervention. During PSYCHOPATHY.COMP, participants will not receive individual therapy (psychotherapy, psychological treatment) by an accredited psychologist or therapist.

    Also known as: Treatment group

  • OtherTreatment as Usual (TAU)

    Participants in the control group will receive the routine support offered in the prison setting, tailored to individual case management and focused on behavioural management and adjustment.

    Also known as: Control group

06

What researchers measure

Primary outcomes

  1. Efficacy Testing: change from eligibility assessment in participant-reported psychopathy (primary outcome) to six-month follow-up

    Modified intention-to-treat (mITT, all participants randomized) and per protocol (PP, only participants who completed a sufficient dose) analyses of mean differences in participant-reported psychopathy between PSYCHOPATHY.COMP and TAU groups. Measured with the Self-Report Psychopathy Scale - Short-form (SRP-SF): a 29-item, shortened version of SRP-4 that assesses psychopathy according to the conceptualization of the Hare's Psychopathy Checklist - Revised. SRP-SF measures four facets of psychopathy: interpersonal (INT; 7 items), affective (AFF; 7 items), lifestyle (LIF; 7 items), and antisocial (ANT; 8 items). Items are rated on a five-point Likert-type scale, ranging from 1: "Strongly disagree" to 5: "Strongly agree". Total and subscale scores are computed by summing the corresponding individual item scores (after correcting for reversed items), with higher scores indicating higher levels of psychopathic traits.

    Time frame: From eligibility to six months after the end of treatment. Measured at eligibility (T0), baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment

  2. Efficacy Testing: change from eligibility assessment in participant-reported psychopathy (primary outcome) to six-month follow-up

    mITT and PP analyses of mean differences in participant-reported psychopathy between PSYCHOPATHY.COMP and TAU groups. Measured with the Levenson Self-Report Psychopathy Scale (LSRPS): a 26-item questionnaire assessing psychopathy in two domains: primary (selfish, callous, uncaring and manipulative; 16 items) and secondary (impulsivity and behavioural control; 10 items) psychopathy, which aligns with the conceptualization of the Hare's Psychopathy Checklist - Revised. Items are rated on a four-point Likert-type scale, ranging from 1: "Strongly disagree" to 4: "Strongly agree". Total and subscale scores are computed by summing the corresponding individual item scores (after correcting for reversed items), with higher scores indicating higher levels of psychopathy.

    Time frame: From eligibility to six months after the end of treatment. Measured at eligibility (T0), baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment

Secondary outcomes

  1. Efficacy Testing: changes from baseline in participant-reported emotional regulation (secondary outcome) to six-month follow-up

    mITT and PP analyses of mean differences in emotional regulation between PSYCHOPATHY.COMP and TAU groups. Measured with State-Trait Anger Expression Inventory (STAXI): 44-item self-report questionnaire assessing anger-state (how one feels in the present moment; 10 items), anger-trait (how one generally feels, 10 items; with two factors: temperament and angry reaction, 4 items each), and anger-expression (how one generally reacts or behaves when feeling enraged or angry, 24 items; three factors: anger expression-in, anger expression-out and anger control, 8 items each). Items are rated on a four-point Likert-type scale from 1: "Not at all/almost never" to 4: "Very much so/almost always". Scale scores are computed by summing item scores, higher scores indicate higher levels of anger. Anger Expression scale is calculated as the sum of Anger Expression-In and Anger Expression-Out minus Anger Control, plus a constant.

    Time frame: From baseline to six months after the end of treatment. Measured at baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment

  2. Efficacy Testing: changes from baseline in participant-reported emotional regulation (secondary outcome) to six-month follow-up

    mITT and PP analyses of mean differences in participant-reported emotional regulation between PSYCHOPATHY.COMP and TAU groups. Measured with the Other As Shamer Scale - 2 (OAS-2), a shorter form of the Other as Shamer scale (OAS). OAS-2 is an 8-item self-report questionnaire measuring external shame (i.e., subject's perception of being negatively judged by others). Items are rated on a five-point Likert-type scale, ranging from 0: "Never" to 4: "Almost always". The scale scores are computed by summing the corresponding individual item scores, with higher scores indicating higher levels of shame.

    Time frame: From baseline to six months after the end of treatment. Measured at baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment

  3. Efficacy Testing: changes from eligibility in participant-reported behavioral regulation (secondary outcome) to six-month follow-up

    mITT and PP analyses of mean differences in participant-reported behavioral regulation between PSYCHOPATHY.COMP and TAU groups. Measured with an institutional behavioral grid (IBG) developed by the research team and previously used. IBG assessed the number/type of disciplinary infractions and the number of days of the punitive measures applied by the prison administration (collected from individual prison record files).

    Time frame: From eligibility to six months after the end of treatment: from eligibility to baseline (T0-T1, pre-treatment), baseline to within one-month after treatment (T1-T2, during treatment), within one-month to six months after treatment (T2-T3, post-treatment)

Other outcomes

  1. Mediation Testing: participant-reported compassion-related variables

    mITT and PP analyses of mean differences in participant-reported emotional regulation between PSYCHOPATHY.COMP and TAU groups. Measured with the Self-Compassion Scale (SCS): a 26-item self-report questionnaire measuring six components (subscales) of self-compassion: self-kindness (5 items), self-judgment (5 items), common humanity (4 items), isolation (4 items), mindfulness (4 items), and overidentification (4 items). Items are rated on a five-point Likert-type scale, ranging from 1: "Almost never" to 5: "Almost always". Scores are computed by averaging item responses (after correcting for reversed items), with higher scores indicating higher levels of self-compassion.

    Time frame: From baseline to six months after the end of treatment. Measured at baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment

  2. Mediation Testing: participant-reported compassion-related variables

    mITT and PP analyses of mean differences in participant-reported emotional regulation between PSYCHOPATHY.COMP and TAU groups. Measured with the Compassion Scale (CS): a 16-item self-report questionnaire measuring compassion towards others, composed of subscales representing kindness (4 items), common humanity (4 items), mindfulness (4 items), and indifference (4 items). Items are rated on a five-point Likert-type scale, ranging from 1: "Almost never" to 5: "Almost always". Scores are computed by averaging item responses (after correcting for reversed items), with higher scores indicating higher levels of compassion for others.

    Time frame: From baseline to six months after the end of treatment. Measured at baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment

  3. Mediation Testing: participant-reported compassion-related variables

    mITT and PP analyses of mean differences in participant-reported emotional regulation between PSYCHOPATHY.COMP and TAU groups. Measured with the Fears of Compassion Scales (FCS): a 38-item self-report questionnaire that comprises three scales measuring: Fears of expressing compassion for others (10 items); Fears of receiving compassion from others (13 items), and Fears of compassion for self (15 items). Items are rated on a five-point Likert-type scale from 0 "Don't agree at all" to 4: "Completely agree". Scores are computed by averaging item responses, with higher scores indicating greater fears of compassion in the respective dimension.

    Time frame: From baseline to six months after the end of treatment. Measured at baseline assessment (T1, pre-treatment), within one month after the end of treatment (T2, post-treatment), and six months (T3, follow-up) after the end of treatment

  4. Moderation Testing: participant-reported personality pathology pre-treatment

    mITT and PP analyses of mean differences in personality pathology between PSYCHOPATHY.COMP and TAU groups. Measured with the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II): a semi-structured diagnostic interview assessing Axis II personality disorders from the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), and the depressive and passive-aggressive personality disorders (included in DSM-IV's appendix). It can be used to diagnose personality disorders categorically (present/absent) and dimensionally (according to the number of criteria met for each diagnosis) and is considered the "gold standard" for Personality Disorders diagnosis. The SCID-II also provides a summary with a pathology profile of scores over the assessed Personality Disorders.

    Time frame: Antisocial Personality Disorder (ASPD) measured at eligibility (T0, pre-treatment) and the other personality diagnosis at baseline assessment (T1, pre-treatment)

07

Study locations

1 of 1 sites recruiting
  • Prisons of the Direção-Geral de Reinserção e Serviços Prisionais (DGRSP)
    Lisbon, Portugal
    Recruiting
    • Ana Cristina Sabino Pestana Neves Subdirector of the DGRSP Organisational Unit, PhD · Contactananeves@egasmoniz.edu.pt · +351 218812200
08

References and documents

Publications

  • Ribeiro da Silva, D., de Carvalho, I. M., & Garofalo, C. (2024). Treatment of youth and adults with psychopathic traits detained in forensic settings: A systematic review. Aggression and Violent Behavior, 76, 101922. https://doi.org/10.1016/j.avb.2024.101922
  • Coelho, L., Paixão, R., & da Silva, J. T. (2010). O Levenson's Self Report Psychopathy Scale (LSRP). Psychologica, 53, 413-421
  • Goss, K., Gilbert, P., & Allan, S. (1994). An exploration of shame measures-I: The other as Shamer scale. Personality and Individual Differences, 17, 713-717. http://dx.doi.org/10.1016/0191-8869(94)90149-X
  • Matos, M., Pinto-Gouveia, J., Gilbert, P., Duarte, C., & Figueiredo, C. (2015). The Other As Shamer Scale-2: Development and validation of a short version of a measure of external shame. Personality and Individual Differences, 74, 6-11. https://doi.org/10.1016/j.paid.2014.09.037
  • Neff, K. D. (2003). Self-Compassion: An Alternative Conceptualization of a Healthy Attitude Toward Oneself. Self and Identity, 2, 85-101. https://doi.org/10.1080/15298860309032
  • Sousa, R., Castilho, P., Vieira, C., Vagos, P., & Rijo, D. (2017). Dimensionality and gender-based measurement invariance of the Compassion Scale in a community sample. Personality and Individual Differences, 117, 182-187. https://doi.org/10.1016/j.paid.2017.06.003
  • Sousa R, Paulo M, Brazao N, Castilho P, Rijo D. Measuring compassion toward others: Dimensionality of the compassion scale in community adolescents and in adolescents with behavioral disorders. Psychol Assess. 2022 Jul;34(7):631-642. doi: 10.1037/pas0001133. Epub 2022 Mar 31. PubMed 35357875 ↗
  • Spielberger, C. D. (1988). Professional Manual for the State-Trait Anger Expression Inventory (STAXI). Odessa, FX: Psychological Assessment Resources
  • Levenson MR, Kiehl KA, Fitzpatrick CM. Assessing psychopathic attributes in a noninstitutionalized population. J Pers Soc Psychol. 1995 Jan;68(1):151-8. doi: 10.1037//0022-3514.68.1.151. PubMed 7861311 ↗
  • Hare, R. D. (2003). Manual for the revised psychopathy checklist (2nd ed.). Toronto, Canada: Multi-Health Systems
  • Paulhus, D. L., Neumann, C. S., & Hare, R. D. (2016). The SRP-4: Self-report psychopaty scale (4th ed.). Toronto, Canada: Multi-Health Systems
  • First, M. B., Gibbon, M., Spitzer, R. L., Williams, J. B. W., & Benjamin, L. S. (1997). Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC: American Psychiatric Press.
  • Gilbert P, McEwan K, Matos M, Rivis A. Fears of compassion: development of three self-report measures. Psychol Psychother. 2011 Sep;84(3):239-55. doi: 10.1348/147608310X526511. Epub 2011 Apr 13. PubMed 22903867 ↗
  • Pommier E, Neff KD, Toth-Kiraly I. The Development and Validation of the Compassion Scale. Assessment. 2020 Jan;27(1):21-39. doi: 10.1177/1073191119874108. Epub 2019 Sep 13. PubMed 31516024 ↗
  • Castilho P, Pinto-Gouveia J, Duarte J. Evaluating the Multifactor Structure of the Long and Short Versions of the Self-Compassion Scale in a Clinical Sample. J Clin Psychol. 2015 Sep;71(9):856-70. doi: 10.1002/jclp.22187. Epub 2015 Apr 22. PubMed 25907562 ↗
  • Silva, D. R., Campos, R., & Prazeres, N. (1999). O Inventário de Estado-Traço de Raiva (STAXI) e sua adaptação para a população portuguesa. Revista Portuguesa de Psicologia, 34, 55-81
  • Seara-Cardoso A, Queiros A, Fernandes E, Coutinho J, Neumann C. Psychometric Properties and Construct Validity of the Short Version of the Self-Report Psychopathy Scale in a Southern European Sample. J Pers Assess. 2020 Jul-Aug;102(4):457-468. doi: 10.1080/00223891.2019.1617297. Epub 2019 Jun 12. PubMed 31188025 ↗
  • Knight, R. A., & Guay, J.-P. (2006). The Role of Psychopathy in Sexual Coercion against Women. In C. J. Patrick (Ed.), Handbook of psychopathy (pp. 512-532). The Guilford Press
  • Hare, R. D. (2020). The PCL-R assessment of psychopathy. In A. R. Felthous & H. Saß (Eds.), The Wiley International Handbook on Psychopathic Disorders and the Law (pp. 63-106). John Wiley & Sons. https://doi.org/10.1002/9781119159322.ch4
  • Brazao N, Rijo D, da Silva DR, do Ceu Salvador M, Pinto-Gouveia J. Personality Pathology Profiles as Moderators of the Growing Pro-Social Program: Outcomes on Cognitive, Emotion, and Behavior Regulation in Male Prison Inmates. J Pers Disord. 2021 Feb;35(1):84-113. doi: 10.1521/pedi_2019_33_424. Epub 2019 Apr 15. PubMed 30985238 ↗
  • Gillespie SM, Jones A, Garofalo C. Psychopathy and dangerousness: An umbrella review and meta-analysis. Clin Psychol Rev. 2023 Mar;100:102240. doi: 10.1016/j.cpr.2022.102240. Epub 2022 Dec 13. PubMed 36608488 ↗
  • Ribeiro da Silva D, Rijo D, Brazao N, Paulo M, Miguel R, Castilho P, Vagos P, Gilbert P, Salekin RT. The efficacy of the PSYCHOPATHY.COMP program in reducing psychopathic traits: A controlled trial with male detained youth. J Consult Clin Psychol. 2021 Jun;89(6):499-513. doi: 10.1037/ccp0000659. PubMed 34264698 ↗

Individual participant data

Plan to share: Yes — The study protocol will be submitted for publication. Participant individual data will be de-identified but will not be shared due to confidentiality and privacy concerns related to the sensitive nature of the participant population. De-identified aggregate data may be available upon reasonable request, subject to ethical approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Start date: March 2026 - no end date

Access criteria: IPD and supporting information will made open on the Open Science Framework (OSF)

Data sharing details ↗ · osf.io

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 19 months after the start.

Of 25 interventional studies with no phase under Antisocial Personality Disorder, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 18, 2026
StartActual
Apr 6, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07481253
Lead sponsor
University of Coimbra
Collaborators
European Regional Development Fund, Portuguese National Funding Agency for Science, Research and Technology (FCT)
Responsible party
Diana Ribeiro da Silva (Assistant Professor, University of Coimbra) — Principal investigator
First posted
Mar 18, 2026
Start date
Apr 6, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Sep 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion